Headache & Migraine
News from the FDA/CDC
FDA approves Reyvow for acute migraine treatment
The approval of lasmiditan (Reyvow) is based on a pair of randomized, double-blind, placebo-controlled trials that included more than 3,000...
From the Journals
Neurostimulation device may treat vertigo in patients with vestibular migraine
In an open-label study, patients used noninvasive vagus nerve stimulation to treat acute vestibular migraine attacks.
Latest News
Postdural puncture headache linked to increased risk of subdural hematoma
The subdural hematoma rate increased slightly, but significantly, to 147 per 100,000 deliveries.
News
Migraines linked to higher risk of dementia
People with a history of migraines may be at greater risk of developing Alzheimer’s disease and dementia.
Conference Coverage
Galcanezumab benefits patients with migraine and medication overuse
PHILADELPHIA – The monoclonal antibody effectively reduces the number of monthly migraine headache days and...
Guidelines
Pediatric, adolescent migraine treatment and prevention guidelines are updated
The guidelines review both pharmacologic and nonpharmacologic options, which have multiplied since the previous guidelines were released in 2004...
Conference Coverage
Ubrogepant shows acute migraine efficacy in triptan nonresponders
PHILADELPHIA – Data from two ubrogepant pivotal trials showed similar migraine pain relief in triptan-ineffective and triptan-effective patients...
Conference Coverage
Asthma hospitalization in kids linked with doubled migraine incidence
PHILADELPHIA – Data from 11 million U.S. pediatric inpatients showed a doubled rate of migraine diagnoses among kids hospitalized for asthma.
Conference Coverage
Lasmiditan is associated with driving impairment
PHILADELPHIA – Impairment is detected at 1.5 hours after dosing and is resolved by 8 hours after dosing.
Conference Coverage
Treatment of episodic cluster headache deviates from recommendations
PHILADELPHIA – Among patients with episodic cluster headache, use of acute medications is high, but use of...